Report Conveys Value and Threats of Nanotechnology Research
|
By LabMedica International staff writers Posted on 04 Feb 2013 |
While scientists constantly increase their knowledge of biology and the surrounding world, all this newly gleaned information has the potential to advance healthcare, it is also possible that the same discoveries can also be used in ways that cause extensive havoc.
A new report assessed the potential for nanosized particles to break the blood-brain barrier (BBB), the closely-knit layers of cells that provide the brain with the highest level of protection in the human body. Some neuroscientists are modifying nanoparticles that can cross the BBB so as to deliver medicines in a targeted and controlled way directly to diseased regions of the brain.
A new article published January 17, 2013, in the journal Nanomedicine: Nanotechnology, Biology and Medicine, came about out of a US Federal Bureau of Investigation (FBI) workshop held at the University of Notre Dame (West Bend, IN, USA) in September 2012, tackles this complicated “dual-use” a feature of nanotechnology research.
“The rapid pace of breakthroughs in nanotechnology, biotechnology, and other fields, holds the promise of great improvements in areas such as medical diagnosis and treatment,” said Dr. Kathleen Eggleson, a research scientist in Notre Dame University’s Center for Nano Science and Technology and the author of the study. “But the risk of misuse of these breakthroughs rises along with the potential benefit. This is the essence of the ‘dual-use dilemma.’”
At the same time, the report noted, “nanoparticles designed to cross the BBB constitute a serious threat…in the context of combat.” For instance, it is hypothesized that aerosol delivery of some nanoengineered agent in “a crowded indoor space” could cause serious harm to many people at once. The difficulties presented by dual-use research was highlighted in 2012 when a debate exploded over the publication of findings that indicate how, with several modifications, the H5N1 influenza virus can be altered in a way that would enable it to be transmitted between mammalian populations.
After a self-imposed one-year moratorium on this research, several laboratories worldwide reported that they will resume the research in early 2013. The FBI is actively responding to these advances in the scientific community. “The law enforcement-security community is seeking to strengthen the existing dialogue with researchers,” stated William So, of the FBI’s Biological countermeasures unit. “Science flourishes because of the open and collaborative atmosphere for sharing and discussing ideas. The FBI believes this model can do the same for our two communities [… and] create effective safeguards for science and national interests.”
The scientists and engineers who conduct nanoscale research have the ability and responsibility to consider the public safety features of their research and to act to protect society when necessary, argued Dr. Eggleson. “The relationship between science and society is an uneasy one, but it is undeniable on the whole and not something any individual can opt out of in the name of progress for humanity’s benefit. Thought about dual-use, and action when appropriate, is inherent to socially responsible practice of nanobiomedical science.”
Related Links:
Notre Dame University’s Center for Nano Science and Technology
A new report assessed the potential for nanosized particles to break the blood-brain barrier (BBB), the closely-knit layers of cells that provide the brain with the highest level of protection in the human body. Some neuroscientists are modifying nanoparticles that can cross the BBB so as to deliver medicines in a targeted and controlled way directly to diseased regions of the brain.
A new article published January 17, 2013, in the journal Nanomedicine: Nanotechnology, Biology and Medicine, came about out of a US Federal Bureau of Investigation (FBI) workshop held at the University of Notre Dame (West Bend, IN, USA) in September 2012, tackles this complicated “dual-use” a feature of nanotechnology research.
“The rapid pace of breakthroughs in nanotechnology, biotechnology, and other fields, holds the promise of great improvements in areas such as medical diagnosis and treatment,” said Dr. Kathleen Eggleson, a research scientist in Notre Dame University’s Center for Nano Science and Technology and the author of the study. “But the risk of misuse of these breakthroughs rises along with the potential benefit. This is the essence of the ‘dual-use dilemma.’”
At the same time, the report noted, “nanoparticles designed to cross the BBB constitute a serious threat…in the context of combat.” For instance, it is hypothesized that aerosol delivery of some nanoengineered agent in “a crowded indoor space” could cause serious harm to many people at once. The difficulties presented by dual-use research was highlighted in 2012 when a debate exploded over the publication of findings that indicate how, with several modifications, the H5N1 influenza virus can be altered in a way that would enable it to be transmitted between mammalian populations.
After a self-imposed one-year moratorium on this research, several laboratories worldwide reported that they will resume the research in early 2013. The FBI is actively responding to these advances in the scientific community. “The law enforcement-security community is seeking to strengthen the existing dialogue with researchers,” stated William So, of the FBI’s Biological countermeasures unit. “Science flourishes because of the open and collaborative atmosphere for sharing and discussing ideas. The FBI believes this model can do the same for our two communities [… and] create effective safeguards for science and national interests.”
The scientists and engineers who conduct nanoscale research have the ability and responsibility to consider the public safety features of their research and to act to protect society when necessary, argued Dr. Eggleson. “The relationship between science and society is an uneasy one, but it is undeniable on the whole and not something any individual can opt out of in the name of progress for humanity’s benefit. Thought about dual-use, and action when appropriate, is inherent to socially responsible practice of nanobiomedical science.”
Related Links:
Notre Dame University’s Center for Nano Science and Technology
Latest BioResearch News
- D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
- New Genetic Cause Identified for Neurodevelopmental Disorder
- New Genetic Discovery Could Support Precision Diabetes Care
- Inherited Genetic Differences Help Explain Variable CAR T-Cell Therapy Outcomes
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
Channels
Clinical Chemistry
view channel
Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease
Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more
New Chairside Oral Swab Test Could Guide Biopsy Decisions in Oral Cancer
Oral squamous cell carcinoma can be difficult to triage at the point of care, resulting in frequent biopsies of lesions that ultimately prove benign. Limited access to pathology services in many communities... Read moreMolecular Diagnostics
view channel
Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read more
Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
Invasive fungal infections disproportionately affect immunocompromised patients, while diagnostic delays can contribute to substantial morbidity and mortality. Existing methods often depend on invasive... Read morePathology
view channel
AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
Molecular profiling is essential for characterizing solid tumors, but many laboratories still rely on separate genetic assays to detect alterations such as TP53 mutations. These workflows can be resource-intensive... Read more
AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
Selecting patients for antibody-drug conjugates (ADCs) increasingly requires broader tissue context, as target expression alone may not fully explain therapeutic response. Laboratories and translational... Read more
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more







